Reviewer: Thomas Dilling, MD
Abramson Cancer Center of the University of Pennsylvania
Ultima Vez Modificado: 17 de octubre del 2005
Presenter: R. Poetter
Presenter's Affiliation: Dept. of Radiotherapy and Radiobiology, Medical University of Vienna
Type of Session: Plenary
In treating early-stage breast cancers with favorable prognostic features, the question has been raised as to whether oncologists might be overtreating these patients. In other words, is it necessary to treat an elderly patient with as aggressive a treatment regimen as a younger patient?
The recent CALGB 9343 trial looked at patients with age >70 years, ER+ T1 tumors, who had lumpectomy with negative margins. These patients were treated with either radiation/tamoxifen or tamoxifen alone. With 7 year median follow-up, disease-free survival (DFS) was statistically greater in the patients treated with radiation (99%) vs those treated with tamoxifen alone (94.4%), with equivalent rates of breast preservation in patients who did recur.
This trial, conducted independently by the Austrian Breast and Colorectal Cancer Group looked at a similar question, as addressed by this study.
Materials and Methods
The follow-up on this study is still relatively short and further analysis will be necessary in the future. Nonetheless, it is an interesting confirmatory study of the results from the CALGB trial. The rates of local control in this population with early stage cancer are excellent overall to date. The addition of radiation therapy clearly reduces the rate of local recurrence.
A difficulty which oncologists still face is in deciding which patients would benefit from radiotherapy. If a patient with a T1N0, favorable-prognosis tumor is otherwise quite elderly and debilitated, it would be reasonable to consider omitting radiotherapy for treatment with hormonal therapy only as the local control is excellent. However, while age is a convenient metric to use when treating patients, it is nonetheless vital to remember that not all patients of the same age have the same life expectancy. If a patient is expected to live for a number of years to come, based upon overall good health and performance status, it would make more sense to treat the patient with XRT to further reduce the chances of local recurrence. But there remains a group of patients who are "in between" these extremes. This requires a difficult clinical judgment on the part of the treating oncologists, which needs to be discussed with the patient. Individualized treatment is clearly of vital importance in treating the elderly patient with favorable, early-stage breast cancer.